10.6084/M9.FIGSHARE.20367467
Kim A. Papp
Kim A.
Papp
Henrik Thoning
Henrik
Thoning
Sascha Gerdes
Sascha
Gerdes
Matteo Megna
Matteo
Megna
University of Naples Federico II
Henrik Brandi
Henrik
Brandi
Marie Y. Jablonski Bernasconi
Marie Y. Jablonski
Bernasconi
Oriol Yélamos
Oriol
Yélamos
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
<p>Once-daily, fixed-combination calcipotriol 50 μg/g (Cal) plus betamethasone dipropionate 0.5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream.</p> <p>Anchored and unanchored MAIC analyses were conducted using individual patient data (IPD) from five Cal/BD foam trials and two trials of Cal/BD cream. Outcomes of interest were the proportion of patients with Physician's Global Assessment (PGA) success and the mean reduction in modified Psoriasis Area and Severity Index (mPASI).</p> <p>In the anchored MAIC, patients were more likely to achieve PGA success after 4 weeks of Cal/BD foam than after 8 weeks of Cal/BD cream and had larger mean improvements in mPASI (<i>p</i> < .01 in EU mPASI analysis). In unanchored analyses, 4 weeks of Cal/BD foam treatment was statistically significantly more efficacious in inducing PGA success than 8 weeks of Cal/BD cream (<i>p</i> < .01 in five of six comparisons). Mean reductions in mPASI were consistently statistically significantly greater with Cal/BD foam than with Cal/BD cream.</p> <p>Use of Cal/BD foam consistently shows significantly greater improvements in PGA and mPASI outcomes, compared with Cal/BD cream.</p>
Physiology
Pharmacology
Ecology
69999 Biological Sciences not elsewhere classified
Science Policy
Hematology
Taylor & Francis
2022
2022-07-25
2022-12-05
Journal contribution
82838 Bytes
10.1080/09546634.2022.2095330
CC BY 4.0